<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834262</url>
  </required_header>
  <id_info>
    <org_study_id>BIASP-3669</org_study_id>
    <nct_id>NCT00834262</nct_id>
  </id_info>
  <brief_title>Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients</brief_title>
  <official_title>A Multi Centre, Open Label, Non-Randomized, Non Interventional, Observational Study on the Safety and Efficacy of Biphasic Insulin Aspart (NovoMix® 30, NovoMix® 50 and NovoMix® 70 or Combinations) in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia. The aim of this observational study is to evaluate the
      safety profile and clinical effectiveness of using various pre-mixes of Biphasic Insulin
      Aspart under routine clinical practice conditions in Israel in Type 2 Diabetes patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of all hypoglycaemic episodes</measure>
    <time_frame>during 13 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse drug reactions</measure>
    <time_frame>during 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>during 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of all major hypoglycaemic (daytime and nocturnal) episodes</measure>
    <time_frame>during 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of all minor and symptomatic (daytime and nocturnal) hypoglycaemic episodes</measure>
    <time_frame>during 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of major hypoglycaemic episodes related to omission of a meal after injection</measure>
    <time_frame>during 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of major hypoglycaemic episodes related to physical exercise of at least 30 min duration</measure>
    <time_frame>during 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (BMI) change</measure>
    <time_frame>at the end of the study after 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c change</measure>
    <time_frame>at the end of the study after 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching the target of HbA1c of 7.0% or less</measure>
    <time_frame>at the end of the study after 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability in fasting blood glucose values and average (mean) fasting blood glucose level</measure>
    <time_frame>at the end of the study after 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average post-breakfast (2h), post-lunch (2h), post-dinner (2h) blood glucose level</measure>
    <time_frame>at the end of the study after 13 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">339</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 30</intervention_name>
    <description>Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation</description>
    <arm_group_label>A</arm_group_label>
    <other_name>NovoMix® 30</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 50</intervention_name>
    <description>Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biphasic insulin aspart 70</intervention_name>
    <description>Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient with type 2 diabetes who has HbA1c greater than 7% on insulin with or without
        OAD and who needs intensification of treatment with either NovoMix® 30, NovoMix® 50 or
        NovoMix® 70 or combinations, will be eligible A nonrandomized sample of approximately 325
        subjects with Type 2 diabetes mellitus will be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with type 2 diabetes who has HbA1c greater than 7% on insulin with or
             without OAD and who needs intensification of treatment with either NovoMix® 30 or
             NovoMix® 50 or NovoMix® 70 or combinations, will be eligible

        Exclusion Criteria:

          -  Subjects with a hypersensitivity to biphasic insulin aspart or to any of the
             excipients. Particular attention should be paid to the drug interactions that are
             listed within the product local label.

          -  Women who are pregnant, breast feeding or have the intention of becoming pregnant
             within the next 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44425</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Biphasic Insulins</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

